Table 2.
Prevalence of aspirin induced asthma in children, analysed by population and test method. Values are numbers (percentages) unless stated otherwise
| Trial | Study design | Mean age (years) | Study population | Authors' definition of positive response | Oral provocation testing | Oral provocation testing and verbal history of aspirin induced asthma | Verbal history alone |
|---|---|---|---|---|---|---|---|
| Group 1: Unselected asthma population*:
| |||||||
| Marquett et al 199220 | Randomised, double blind, placebo controlled | 13.5 | Asthma clinic: moderately severe asthma | Reduction in FEV1 >2 SD from mean placebo response (all positives were >20% reduction in FEV1) | 5/54 (9) | 7/56 (13) | — |
| Rachelefsky et al 197521 | Open challenge | 9.6 | Outpatients | Reduction in peak expiratory flow rate ≥20% | 0/32 (0) | — | — |
| Schuhl and Pereyra 197923 | Single blind | 9.0 | Asthma clinic: chronic asthma | Reduction in peak expiratory flow rate and FEV1 ≥20% | 6/29 (20.7) | — | — |
| Pearson 196327 | Medical records | Range 6-16 | Allergy and asthma clinic | Not available | — | — | 25/1298 (1.9) |
| Total (95% CI)† | — | — | — | — | 5.0 (0 to 14.0)‡ | 12.5 (3.8 to 21.2) | 1.9 (1.2 to 2.6) |
| Group 3: Preselected population with no history of sensitivity§:
| |||||||
| Vedanthan et al 199722 | Double blind, placebo controlled | 12.5 | Outpatients, chronic asthma (severity varied). All drugs discontinued 12 hours before testing | Reduction in FEV1 >20% | 3/25 (12) | — | — |
| Milosevic 199019 | Double blind, placebo controlled | 13.6 | Allergy clinic | Reduction in FEV1 ≥30% from baseline for up to four hours | 9/50 (18) | — | — |
| Total (95% CI)† | — | — | — | — | 15.5 (4.2 to 26.8) | — | — |
FEV1=forced expiratory volume in one second.
No studies found for preselected population with a history of aspirin induced asthma or with markers of increased risk or likelihood of aspirin induced asthma (group 2).
*
Includes patients with and without history of aspirin induced asthma and with and without markers of increased risk or likelihood of aspirin induced asthma.
†
Calculated from pooling incidence rate in individual studies.
‡
Lower bound truncated at 0.
§
Includes patients without history of aspirin induced asthma or without markers of increased risk or likelihood of aspirin induced asthma.